Reviva Pharmaceuticals Holdings Inc (NASDAQ:RVPHW) — Stock Price
Reviva Pharmaceuticals Holdings Inc (NASDAQ:RVPHW) is currently trading at $0.00 USD, down 16.67% today. Over the past 52 weeks, shares have ranged between $0.00 and $0.09. This page tracks Reviva Pharmaceuticals Holdings Inc's live share price on the NASDAQ exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see Reviva Pharmaceuticals Holdings Inc (RVPHW) total market value.
Reviva Pharmaceuticals Holdings Inc (RVPHW) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Reviva Pharmaceuticals Holdings Inc's daily closing share price and trading volume on the NASDAQ exchange over the past year, giving a clear view of recent price momentum and liquidity.
Reviva Pharmaceuticals Holdings Inc Income Statement — Revenue, Profit & Earnings by Year
Reviva Pharmaceuticals Holdings Inc's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | — | — | — | — | $724.74K |
| Gross Profit | — | — | — | — | $-724.74K |
| Research & Development | $22.91 Million | $31.42 Million | $18.95 Million | $4.85 Million | $295.15K |
| SG&A | $7.89 Million | $8.08 Million | $5.36 Million | $5.25 Million | $2.14 Million |
| Total Operating Expenses | $30.80 Million | $39.50 Million | $24.31 Million | $10.10 Million | $2.43 Million |
| Operating Income | $-30.80 Million | $-39.50 Million | $-24.31 Million | $-10.10 Million | $-2.43 Million |
| EBITDA | $-29.88 Million | $-39.21 Million | $-24.11 Million | $-8.51 Million | $-2.33 Million |
| EBIT | $-60.68 Million | $-78.71 Million | $-24.31 Million | $-10.10 Million | $-2.43 Million |
| Interest Expense | $18.50K | $33.73K | $182.80K | $2.41K | $1.45 Million |
| Income Before Tax | $-29.90 Million | $-39.24 Million | $-24.32 Million | $-8.52 Million | $-3.78 Million |
| Income Tax Expense | $19.51K | $16.95K | $20.78K | $6.00K | $800.00 |
| Net Income | $-29.92 Million | $-39.26 Million | $-24.34 Million | $-8.52 Million | $-3.78 Million |
Reviva Pharmaceuticals Holdings Inc Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Reviva Pharmaceuticals Holdings Inc's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Assets | $15.50 Million | $23.70 Million | $18.92 Million | $31.40 Million | $8.76 Million |
| Total Current Assets | $14.68 Million | $23.70 Million | $18.92 Million | $31.40 Million | $8.76 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | — | — | — | — | — |
| Net Receivables | — | — | — | — | — |
| Inventory | — | — | — | — | — |
| Property, Plant & Equipment | — | — | — | — | — |
| Goodwill | — | — | — | — | — |
| Total Liabilities | $14.69 Million | $17.98 Million | $10.53 Million | $2.72 Million | $3.30 Million |
| Total Current Liabilities | $14.60 Million | $17.18 Million | $9.96 Million | $2.34 Million | $1.33 Million |
| Long-term Debt | — | — | — | — | — |
| Net Debt | $-13.02 Million | $-23.37 Million | $-18.52 Million | $-29.69 Million | $-8.76 Million |
| Total Stockholder Equity | $812.57K | $5.72 Million | $8.39 Million | $28.69 Million | $5.47 Million |
| Retained Earnings | $-164.27 Million | $-134.35 Million | $-95.09 Million | $-66.83 Million | $-58.31 Million |
Reviva Pharmaceuticals Holdings Inc Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Reviva Pharmaceuticals Holdings Inc generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Cash Flow | $-33.54 Million | $-28.32 Million | $-18.96 Million | $-10.67 Million | $-4.07 Million |
| Capital Expenditures | $4.00 | $3.00 | $0.00 | $0.00 | $0.00 |
| Free Cash Flow | $-33.54 Million | $-28.32 Million | $-18.96 Million | $-10.67 Million | $-4.07 Million |
| Investing Cash Flow | — | — | — | — | — |
| Financing Cash Flow | $23.65 Million | $33.17 Million | $7.79 Million | $31.60 Million | $12.83 Million |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | $1.63 Million | $3.41 Million | $176.74K | $106.71K | $0.00 |
| Depreciation | — | — | — | $107.00 | $591.00 |
| Change in Cash | $-9.89 Million | $4.85 Million | $-11.17 Million | $20.93 Million | $8.76 Million |
Reviva Pharmaceuticals Holdings Inc Earnings History — EPS Actual vs. Analyst Estimates
Track Reviva Pharmaceuticals Holdings Inc's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
Earnings history is not currently available for Reviva Pharmaceuticals Holdings Inc.